Corticosteroid therapy does not alter the threshold for contraction- induced injury in dystrophic (mdx) mouse diaphragm

Muscle and Nerve

Volumn 21, Issue 3, 1998, Pages 394-397

  Yang, Living ^a,b   Luo, Jun ^a,b   Petrof, Basil J ^a,b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Corticosteroids; Duchenne muscular dystrophy; Eccentric contractions; Mdx dystrophy; Muscle injury

Indexed keywords

CORTICOSTEROID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOSKELETON; DRUG EFFECT; DUCHENNE MUSCULAR DYSTROPHY; ENZYME ACTIVITY; MOUSE; MUSCLE INJURY; MUSCLE STRENGTH; NONHUMAN; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; PROTEIN STABILITY;

EID: 0031907827     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-4598(199803)21:3<394::aid-mus14>3.0.co;2-%23     Document Type: Article

References (22)

1. Anderson JE, McIntosh LM, Poettcker R: Deflazacort but not prednisone improves both muscle repair and fiber growth in diaphragm and limb muscle in vivo in the mdx dystrophic mouse. Muscle Nerve 1996;19:1576-1585.
2. Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C: Deflazacort in Duchenne dystrophy: study of long term effect. Muscle Nerve 1994;17:386-391.
3. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT, Miller JP, Kaiser KK, Florence JM, Pandya S, Signore L, King W, Robinson J, Head RA, Province MA, Seyfried W, Mandel S: Clinical investigation of Duchenne dystrophy: interesting results in a trial of prednisone. Arch Neurol 1987;44:812-817.
4. Burrow KL, Coovert DD, Klein CJ, Bulman DE, Kissel JT, Rammohan KW, Burghes AHM, Mendell JR, and the CIDD Study Group: Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. Neurology 1991;41:661-666.
5. DeSilva S, Drachman DB: Prednisone treatment in Duchenne muscular dystrophy. Long term benefit. Arch Neurol 1987;44:818-822.
6. Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT, Griggs RC, Brooke MH, Miller JP, Robinspn J, King W, Signore L, Pandya S, Schierbecker J, Wilson B: Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41:1874-1877.
7. Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP, and the Clinical Investigation of Duchenne Dystrophy Group: Prednisone in Duchenne dystrophy. Arch Neurol 1991;48:383-388.
8. Guerriero V Jr, Florini JR: Dexamethasone effects on myoblast proliferation and differentiation. Endocrinology 1980;106:1198-1202.
9. Huffman EP, Brown RHJ, Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928.
10. Hudecki MS, Pollina CM, Granchelli JA, Daly MK, Byres T, Wang JC, Hsiao JC: Strength and endurance in the therapeutic evaluation of prednisolone-treated mdx mice. Res Commun Chem Pathol Pharmacol 1993;79:45-60.
11. Jones DA, Newham DJ, Round JM, Tolfree SEJ: Experimental human muscle damage: morphological changes in relation to other indices of damage. J Physiol 1986;375:435-448.
12. Kawai H, Adachi K, Nishida Y, Inui T, Kimura C, Saito S: Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment. J Neurol 1993;240:181-186.
13. Khan MA: Corticosteroid therapy in Duchenne muscular dystrophy. J Neurol Sci 1993;120:8-14.
14. Kissel JT, Burrow KL, Rammohan KW, Mendell JR, CIDD Study Group: Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. Neurology 1991;41:667-672.
15. Kissel JT, Lynn DJ, Rammohan KW, Klein JP, Griggs RC, Moxley RT3d, Cwik VA, Brooke MH, Mendell JR: Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy. Neurology 1993;43:532-536.
16. McCully K, Giger U, Argov Z, Valentine B, Cooper B, Chance B, Bank W: Canine X-Iinked muscular dystrophy studied with in vivo phosphorus magnetic resonance spectroscopy. Muscle Nerve 1991;14:1091-1098.
17. McCully KK, Faulkner JA: Characteristics of lengthening contractions associated with injury to skeletal muscle fibers. J Appl Physiol 1986;61:293-299.
18. McNeil PL, Khakee R: Disruptions of muscle fiber plasma membranes. Role in exercise-induced damage. Am J Pathol 1992;140:1097-1109.
19. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, King W, Signore L, Pandya S, Florence J, Schierbecker J, Robinson J, Kaiser K, Mandel S, Arfken C, Gilder B: Randomized double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592-1597.
20. Menke A, Jockusch H: Decreased osmotic stability of dystrophin-less muscle cells from the mdx mouse. Nature 1991;349:69-71.
21. Mesa LE, Dubrovsky AL, Corderi J, Marco P, Flores D: Steroids in Duchenne muscular dystrophy-deflazacort trial. Neuromusc Disord 1992;1:261-266.
22. Metzinger L, Passaquin A-C, Warter J-M, Poindron P: α-Methylprednisolone promoted skeletal myogenesis in dystrophin-deficient and control mouse cultures. Neurosci Lett 1993;155:171-174.